Drug Trial Radar · NCT06769698
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 14, 2026
Primary completion
Jun 4, 2028
Study completion Dec 28, 2030
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is focused on participants with head and neck cancers who have not been previously treated for head and neck cancer that has come back or spread to other parts of the body, referred to as recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). The study is looking at several other research questions, including: * What side effects may happen from taking the study drugs * How much of each study drug is in the blood at different times * Whether the body makes antibodies against the study drug(s) individually (which could make the study drugs less effective or could lead to side effects) * Compatible research to better understand the study drugs and HNSCC
Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
FDC fianlimab+cemiplimabDrug
Fixed-Dose Combination (FDC) Administered per the protocol
CemiplimabDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Up to 90 days after last study treatment, approximately 58 months
Locations
38 sites in 6 countries. Site status is shown where the registry gives one.
University of California Los Angeles
Los Angeles, California · Recruiting
Samuel Oschin Cancer Center
Los Angeles, California · Recruiting
Orlando Health
Orlando, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
Northwestern University
Evanston, Illinois · Recruiting
St. Elizabeth Healthcare
Edgewood, Kentucky · Recruiting
Norton Cancer Institute
Louisville, Kentucky · Recruiting
Henry Ford Cancer Institute/Henry Ford Health System
Detroit, Michigan · Recruiting
Oncology Hematology West P.C. dba Nebraska Cancer Specialists
Omaha, Nebraska · Recruiting
University of Rochester
Rochester, New York · Recruiting
Ohio State University
Columbus, Ohio · Recruiting
Asplundh Cancer Pavilion
Willow Grove, Pennsylvania · Recruiting
University of Tennessee Medical Center
Knoxville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Joe Arrington Cancer Research & Treatment Center
Lubbock, Texas · Recruiting
Renovatio Clinical
The Woodlands, Texas · Recruiting
Inova Schar Cancer Institute
Fairfax, Virginia · Recruiting
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia · Recruiting
Wide Bay Hospital and Health Service - Cancer Care Services - Bundaberg
Bundaberg, Queensland, Australia · Recruiting
Cairns Hospital
Cairns, Queensland, Australia · Recruiting
Wide Bay Hospital and Health Service
Hervey Bay, Queensland, Australia · Recruiting
Peter MacCallum Cancer Centre (PMCC)
Melbourne, Victoria, Australia · Recruiting
Centre Jean Perrin
Clermont-Ferrand, Auvergne-Rhône, France · Recruiting
Timone Hospital - AP-HM
Marseille, Bordeaux, France · Recruiting
Hopital Europeen Geroges Pompidou AP-HP
Paris, Île-de-France Region, France · Recruiting
Istituto Europeo di Oncologia
Milan, Italy · Recruiting
IRCCS Ospedale San Raffaele
Milan, Lombardy, Italy · Recruiting
Fondazione Irccs Istituto Nazionale dei Tumori di Milano
Milan, Lombardy, Italy · Recruiting
Humanitas Cancer Center
Pieve Emanuele, Milan, Italy · Recruiting
Wojewodzki Szpital im. Sw. Ojca Pio
Przemyśl, Podkarpackie Voivodeship, Poland · Recruiting
Centro Oncologico de Galicia
A Coruña, Spain · Recruiting
University Hospital Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Hospital Universitario Virgen del Rocio
Seville, Andalusia, Spain · Recruiting
Hospital Clinic
Barcelona, Catalonia, Spain · Recruiting
Complejo Hospitalario Universitario de a Coruna
A Coruña, Galicia, Spain · Recruiting
Hospital Universitario de Navarra
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.